Document is current
Any future updates will be listed below
-
Authors
Taylor, Samuel R.
Ramsamooj, Shakti
Liang, Roger J.
Katti, Alyna
Pozovskiy, Rita
Vasan, Neil
Hwang, Seo-Kyoung http://orcid.org/0000-0003-0866-5376
Nahiyaan, Navid
Francoeur, Nancy J.
Schatoff, Emma M.
Johnson, Jared L. http://orcid.org/0000-0003-1802-6527
Shah, Manish A.
Dannenberg, Andrew J.
Sebra, Robert P.
Dow, Lukas E. http://orcid.org/0000-0001-7048-1418
Cantley, Lewis C. http://orcid.org/0000-0002-1298-7653
Rhee, Kyu Y. http://orcid.org/0000-0003-4582-2895
Goncalves, Marcus D. http://orcid.org/0000-0002-0784-9248
- License Information
-
More Information
Article History
Received: 14 April 2020
Accepted: 15 July 2021
First Online: 18 August 2021
Competing interests
: L.C.C. is a founder, shareholder and member of the scientific advisory board of Agios Pharmaceuticals and a founder and former member of the scientific advisory board of Ravenna Pharmaceuticals (previously Petra Pharmaceuticals). These companies are developing therapies for cancer. L.C.C. has received research funding from Ravenna Pharmaceuticals. L.C.C. and M.D.G. are co-founders and shareholders of Faeth Therapeutics, which is developing therapies for cancer. M.D.G. has received speaking and/or consulting fees from Pfizer, Novartis, Petra Pharmaceuticals, Faeth Therapeutics and TruMacro Nutrition. The laboratory of M.D.G. has received financial support from Pfizer. All other authors report no competing interests.
